



Life Molecular Imaging and XingImaging Announce Start of PI-2620 Tau PET Tracer Production in Mainland China

Berlin, Germany, Beijing, China and New Haven, CT, USA, October 24, 2018 – Life Molecular Imaging (LMI) and XingImaging announced today that production of LMI's ^{18}F -labeled Tau PET imaging agent PI-2620 has commenced at XingImaging sites in China.

LMI and XingImaging leveraged their joint resources to establish broad availability for clinical trial supply supporting LMI's product development efforts, clinical research studies and pharmaceutical drug development trials.

LMI continues to expand the global availability of its tau PET tracer PI-2620. XingImaging LLC, a radiopharmaceutical production and positron emission tomography (PET) acquisition company operating in Mainland China will actively incorporate PI-2620 into their network.

"PI-2620 is a next generation investigational PET tracer with favorable clinical properties designed to identify pathological tau deposits in the brain", said Andrew Stephens, M.D., Ph.D., Chief Medical Officer of Life Molecular Imaging, *"Life Molecular Imaging continues to expand the availability of its innovative molecular imaging agent PI-2620 for clinical investigations and drug development trials."* Ludger Dinkelborg, Ph.D., Managing Director at LMI *added "The cooperation with XingImaging in China is a major step forward as we continue on our way to extend our PI-2620 clinical supply network globally."*

"XingImaging is committed to production of radiotracers to support clinical trials in China and we are excited to be working with LMI and PI-2620. Most importantly, XingImaging's radiotracer production and PET imaging capabilities will help enable AD patients in China to participate in therapeutic clinicals trial testing novel AD investigational drugs," says Gilles Tamagnan, Ph.D., CEO XingImaging, LLC.

About PI-2620

PI-2620 is an ^{18}F -labeled investigational PET tracer that was discovered in a research collaboration between LMI and AC Immune, a Swiss-based clinical stage biopharmaceutical company focused on neurodegenerative diseases. LMI has the exclusive, world-wide license for research, development and commercialization of tau PET tracers generated within the discovery program.

About Life Molecular Imaging (LMI)

LMI (formerly Piramal Imaging) was formed in 2012 with the acquisition of the molecular imaging research and development portfolio of Bayer Pharma AG, and is now part of the Alliance Medical Group, an integrated business including research and development laboratories, a network of cyclotrons, radiopharmacies and imaging facilities. By developing novel PET tracers for molecular imaging, LMI is focusing on a key field of modern medicine. LMI strives to be a leader in the Molecular Imaging field by developing innovative products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life.

For more information, please visit <https://life-mi.com>



About XingImaging LLC

A privately held Delaware limited liability company (LLC) based in New Haven, CT. XingImaging LLC is a specialty radiopharmaceutical production and PET acquisition CRO formed in January 2018 to fill a unique clinical research role in China. XingImaging, is a US based biomarker imaging company focused on conducting radiopharmaceutical imaging trials in China. With well-established study teams in China and the US, XingImaging works in collaboration with biotech and pharmaceutical companies for the testing and advancement of therapeutics through brain imaging.

For more information, please visit <http://www.xingimaging.com>.

###